Zacks Research Issues Pessimistic Forecast for BAX Earnings

Baxter International Inc. (NYSE:BAX - Free Report) - Stock analysts at Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for Baxter International in a research note issued on Thursday, May 22nd. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will post earnings per share of $0.63 for the quarter, down from their prior forecast of $0.66. The consensus estimate for Baxter International's current full-year earnings is $2.48 per share. Zacks Research also issued estimates for Baxter International's Q2 2026 earnings at $0.61 EPS, Q4 2026 earnings at $0.77 EPS and Q1 2027 earnings at $0.57 EPS.

A number of other research analysts have also weighed in on BAX. Wells Fargo & Company dropped their price objective on Baxter International from $36.00 to $33.00 and set an "equal weight" rating on the stock in a report on Friday, May 2nd. Argus upgraded shares of Baxter International from a "hold" rating to a "buy" rating in a research note on Monday, February 24th. JPMorgan Chase & Co. decreased their price objective on shares of Baxter International from $38.00 to $36.00 and set a "neutral" rating on the stock in a report on Friday, February 21st. Barclays increased their target price on shares of Baxter International from $39.00 to $41.00 and gave the company an "overweight" rating in a report on Monday, March 10th. Finally, Morgan Stanley reduced their price objective on Baxter International from $30.00 to $28.00 and set an "underweight" rating for the company in a report on Monday, May 5th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Baxter International currently has an average rating of "Hold" and an average target price of $37.25.

Baxter International Stock Performance

NYSE BAX traded down $0.08 on Monday, hitting $30.45. 222,242 shares of the company's stock were exchanged, compared to its average volume of 4,458,173. The firm has a market cap of $15.63 billion, a price-to-earnings ratio of -23.80, a P/E/G ratio of 0.93 and a beta of 0.63. The firm's 50-day moving average price is $30.54 and its two-hundred day moving average price is $31.53. Baxter International has a fifty-two week low of $26.25 and a fifty-two week high of $40.49. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.43 and a quick ratio of 1.09.

Baxter International (NYSE:BAX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.14. Baxter International had a positive return on equity of 16.67% and a negative net margin of 5.05%. The company had revenue of $2.63 billion for the quarter, compared to the consensus estimate of $2.59 billion. During the same period last year, the business posted $0.65 EPS. The company's revenue was up 5.4% on a year-over-year basis.

Baxter International Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 1st. Investors of record on Friday, May 30th will be given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 2.23%. The ex-dividend date of this dividend is Friday, May 30th. Baxter International's dividend payout ratio is presently -61.82%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Zions Bancorporation National Association UT acquired a new position in shares of Baxter International in the first quarter valued at approximately $27,000. Rossby Financial LCC purchased a new stake in Baxter International in the 1st quarter worth approximately $29,000. CoreFirst Bank & Trust purchased a new stake in Baxter International in the 4th quarter worth approximately $26,000. Riverview Trust Co raised its holdings in Baxter International by 5,488.2% in the 4th quarter. Riverview Trust Co now owns 950 shares of the medical instruments supplier's stock valued at $28,000 after acquiring an additional 933 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB lifted its stake in shares of Baxter International by 48.1% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 2,021 shares of the medical instruments supplier's stock worth $69,000 after purchasing an additional 656 shares during the period. Institutional investors and hedge funds own 90.19% of the company's stock.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.